Microfluidic channel biochip detection apparatus and use method
By placing the blood reagent unit and the biochip unit separately and can be flexibly combined, the problem of limited types of reagents in the prior art is solved, flexible assembly and efficient detection are achieved, and maintenance and maintenance are reduced. Cost of use.
Patent Information
- Application Number
- PCT/CN2024/086983
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-02
- Filing Date
- 2024-04-10
- Publication Date
- 2024-11-14
AI Technical Summary
The existing micro-flower biochip detection device has limited types of reagents on the blood micro-flower, and the frequency of different reagents is used differently, resulting in waste. When the reagents on a certain micro-flower are exhausted or damaged. The failure to detect specific components normally, resulting in the device being no longer available.
Place the blood reagent unit and the biochip unit separately, and can be combined or separated from each other. Select the corresponding reagent and chip as needed to assemble it into the required detection device. Blood and detection liquid flow through different microflow channels to the biochip to reduce Liquids interfere with each other, saving space and allowing vertical stack microflowers for flexible combination and disassembly.
It realizes flexible selection of reagents and chips as needed, reduces waste and maintenance costs, improves detection flexibility and efficiency, and reduces the thickness and use costs of equipment.
Smart Images

Figure CN2024086983_14112024_PF_FP_ABST
Abstract
Description
Microfluidic biochip detection device and usage method
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 500,647, filed May 8, 2023, the disclosure of which is incorporated herein by reference in its entirety. Technical Field
[0003] The present invention relates to a microfluidic biochip detection device and a method of use. In particular, reagents that react with blood components and biochips that react with detection fluid and blood are placed in a blood reagent unit and a biochip unit respectively, thereby increasing usage flexibility and reducing overall costs. Background Art
[0004] Blood tests can provide important information about the human body's condition. However, traditional hospital blood tests are often labor-intensive and time-consuming and cannot provide real-time and effective information. Therefore, in recent years, the use of micro-electro-mechanical systems (MEMS) to form miniaturized detection devices on a substrate biochip has become a hot field. In this way, compared with traditional blood tests, the amount of blood sample and reagent required are smaller, the reaction speed is faster, and the accuracy is higher. In particular, reagents or microstructures that can capture and concentrate antibodies, antigens, proteins and other components in specific blood cells or plasma can be designed for different diseases and different blood components to be tested. In other words, various chips can be customized. Biochips have many specific designs and development paths. For introductory introductions, please refer to the National Taiwan University Electrical Engineering Science Series: https: / / ee.ntu.edu.tw / upload / hischool / doc / 2013.11.pdf or the Science and Instruments New Knowledge Volume 29, Issue 2: https: / / www.tiri.narl.org.tw / Files / Doc / Publication / InstTdy / 160 / 01600670.pdf.
[0005] In recent years, with the advancement of semiconductor and microfluidic technologies, a common microfluidic biochip detection device features a biochip and microfluidic channels placed on the same substrate. Each microfluidic channel has an opening adjacent to the biochip and another opening for fluid entry. One or more of the microfluidic channels contain one or more reagents. In this manner, the blood to be tested first interacts with the reagents as it flows through the microfluidic channels before reaching the biochip and interacting with it, altering its state. For example, red blood cells (RBCs) in the blood to be tested are first solidified and precipitated by an erythrocyte precipitant in the microfluidic channels. Only then does the treated blood come into contact with the biochip. At this point, the miniaturized detection devices on the biochip (such as microelectrodes or microrods with numerous reactive groups on their surfaces) interact with the blood to be tested, which has lost at least some of its RBCs (e.g., by binding to each other and losing its reactivity). Separately, the test fluid flows through the reagent-free microfluidic channels before reaching the biochip. The interaction between the test fluid and the biochip produces two different sets of data, before and after contact between the biochip and blood. By comparing these two sets of data, the test results of the blood to be tested can be obtained (or the results of the interaction between the blood and the reagent can be inferred).
[0006] However, this common design still has some problems, although it has advantages such as simple manufacturing process and low risk of liquid leakage. Since the biochip, the microfluidic channel for the test liquid, and the microfluidic channel for blood containing reagents are all on the same substrate, if the number of reagents on the blood microfluidic channel is small, the types of blood components that can be detected are limited. If more than one reagent is on the same blood microfluidic channel, their effects on the blood testing will inevitably interfere with each other. Therefore, a common design is to have multiple blood microfluidic channels on the same substrate, and each microfluidic channel only has one reagent. However, such a design not only has the problem of large substrate area occupied by the increased number of microfluidic channels, but also has the problem of waste caused by the different frequencies of use of different reagents (or the different probabilities of different types of blood tests). After all, if the reagent on a blood microfluidic channel is exhausted or damaged and cannot normally detect a specific component in the blood, the entire microfluidic biochip detection device can no longer be used to detect this specific component in the blood.
[0007] Obviously, there is a need to improve existing microfluidic biochip detection devices so as to more efficiently utilize existing biochips.
[0008] Summary of the Invention
[0009] The present invention provides a microfluidic biochip detection device and its use method. The basic concept of the present invention is to place the blood microfluidic channel containing the reagents and the biochip used to interact with the test fluid and blood, respectively, on two separate hardware devices, allowing these two hardware devices to be combined or separated. Thus, depending on which specific component or components in the blood need to be detected, hardware devices containing the corresponding blood microfluidic channel and the corresponding specific biochip can be selected and then combined to form the required microfluidic biochip detection device. Then, the test fluid, blood, and test fluid are sequentially fed into the microfluidic biochip detection device. The two sets of data obtained from the reaction between the biochip and the test fluid before and after contact between the blood and the biochip are compared to complete the detection of the specific component in the blood to be tested.
[0010] According to the basic concept of the present invention, the present invention provides a microfluidic biochip detection device comprising a blood reagent unit and a biochip unit. The blood reagent unit has a first opening, a second opening, and a first microfluidic channel. Blood entering the blood reagent unit through the first opening first flows through the first microfluidic channel located within the blood reagent unit before flowing out of the blood reagent unit through the second opening. The biochip unit has a third opening, a fourth opening, a second microfluidic channel, a third microfluidic channel, and a biochip. Blood from the blood reagent unit entering the biochip unit through the third opening flows through the second microfluidic channel located within the biochip unit and reaches the biochip located within the biochip unit. The detection fluid entering the biochip unit through the fourth opening flows through the third microfluidic channel located within the biochip unit and reaches the biochip. Furthermore, at least one reagent is located in the first microfluidic channel for reacting with a component of the blood flowing through it. Furthermore, the second microfluidic channel and the third microfluidic channel are separated from each other, allowing the blood and the detection fluid to flow to the biochip separately.
[0011] Clearly, compared to existing technologies, the microfluidic biochip detection device proposed in this invention changes the relative relationship between the hardware that processes blood and the hardware that uses the biochip, as well as the relative relationship between the microchannels through which blood flows and the microchannels through which the test fluid flows, and the biochip. However, existing reagents and biochips can be directly used. Conventional technology places all microchannels and biochips on the same plane (the same substrate surface), which inevitably leads to a limited number of microchannels (or, more accurately, the number of microchannel openings) near a given biochip that can allow blood / test fluid to flow into the biochip. In contrast, the present invention allows the blood and test fluid flowing through different microchannels to flow to the biochip separately, that is, different microchannels and biochips are arranged separately (for example, each microchannel is arranged on the left and right, above the side, above, or even perpendicular to each other of the biochip). This approach not only saves the occupied area (such as the area occupied by the medical testing workbench), but also allows the number of microchannels corresponding to the same biochip to be unlimited (for example, multiple microchannels can be stacked vertically upwards), and also allows different microchannels to be completely separated, thereby minimizing the possibility of different liquids interfering with each other (reducing the possibility of unexpected situations where a microchannel opening of an adjacent biochip reaches the biochip due to movement inertia, etc.).
[0012] In particular, compared to the prior art, the microfluidic biochip detection device proposed in the present invention separates the portion related to blood flow and reagents from the portion related to the test fluid and biochip into two parts. Therefore, the present invention also allows the blood reagent unit and the biochip unit to be detachably connected to each other. In other words, the same biochip unit can be combined with multiple different blood reagent units (e.g., different blood reagent units containing different reagents) at different times and in different situations, as long as the reagent-treated blood from the blood reagent unit can flow smoothly into the biochip unit during each combination. Of course, when the two units are connected, they must be tightly coupled to prevent blood leakage. Specifically, the second opening of the blood reagent unit is connected to the third opening of the biochip unit so that blood does not leak out of the two units during the process of flowing from the blood reagent unit to the biochip unit. Clearly, by using the microfluidic biochip detection device proposed in the present invention, different blood reagent units can be combined with the biochip unit to perform the test when different blood components need to be tested (or when different reagents are needed to treat the blood). In this way, the structure of the blood reagent unit can be simplified to only a few or even only one reagent per blood reagent unit. This not only eliminates the need to excessively increase the thickness of the entire microfluidic biochip detection device due to the continuous increase in the types of reagents that may be used, but also increases the flexibility in the actual use of the microfluidic biochip detection device, because only the required blood reagent unit needs to be selected as needed.
[0013] The specific structural designs of the blood reagent unit and the biochip unit are not necessarily limited and can be varied in many ways. Generally speaking, to facilitate user operation and facilitate the flow of blood and test fluid, as well as to ensure smooth blood circulation, the second opening is immediately adjacent to the third opening, the first and fourth openings are located on the same side of the microfluidic biochip detection device, and the first and fourth openings are located on opposite sides of the microfluidic biochip detection device as the biochip. Furthermore, to reduce the impact of impurities and other substances on the biochip, a first filter can be placed at the first opening to filter impurities from the initial blood sample. A second filter can also be placed between the second and third openings to filter impurities generated by the reaction between the blood and the reagents. Furthermore, the first microchannel can contain a specific reagent in only one portion, or different reagents can be placed in different portions. Any reagent can react with a specific component of the blood. In other words, different reagents can react differently with different blood components, or react differently with different blood components. Furthermore, the types of reagents and how they are placed in the microchannel can be directly based on existing technologies. For example, at least one reagent may be coated on the first microfluidic channel, and possible types of reagents include but are not limited to the following: separation agent, red blood cell sedimentation agent, white blood cell sedimentation agent, activated carbon and silver nitrate.
[0014] For example, one design is a double-layer structure consisting of a first layer and a second layer arranged in sequence, wherein the first opening is located in the first layer, and the second opening and the first microchannel are located in the second layer. In other words, the interface with the outside world is on the first layer, and everything else is on the second layer, such as different reagents located in different parts of the second layer. Another design is a three-layer structure consisting of a first layer, a third layer, and a fourth layer arranged in sequence, wherein the first opening is located in the first layer, the second opening is located in the third layer, and the first microchannel is located in the third and fourth layers. In other words, the interface with the outside world is on one layer, the interface with the biochip unit is on another layer, and the different reagents are located in different parts of the two layers that are not interfaces with the outside world, thereby leaving more space for the first microchannel and reagents. Another design is a three-layer structure consisting of a first layer, a third layer, and a fourth layer arranged in sequence, wherein the first opening is located in the first layer, the second opening is located in the third layer, and the first microchannel is located in the fourth layer. The third layer further includes a first groove and a second groove, and the first microchannel is connected to the first groove and the second groove, respectively, so that at least one reagent is located in the portion of the first microchannel between the first groove and the second groove. In other words, the interface with the outside world is in one layer, the interface with the biochip unit is in another layer, and different reagents are located in different portions of the two layers that are not external interfaces. This provides more space for the first microchannel and reagents. The two grooves provide a reservoir-like buffering function at the point where blood first enters and at the point where blood is about to leave, respectively, to ensure stable and continuous blood flow.
[0015] For example, one design is a two-layer structure consisting of a fifth and sixth layer arranged in sequence, with the fourth opening located on the fifth layer, the third opening on the sixth layer, the second and third microfluidic channels on the sixth layer, and the biochip at the bottom of the sixth layer. In other words, the interface with the outside world is on one layer, while the various microfluidic channels and the biochip are on another layer, thereby simplifying the relevant structure. Another design is a three-layer structure consisting of a fifth, seventh, and eighth layer arranged in sequence, with the fourth opening located on the fifth layer, the third opening and the second microfluidic channel on the seventh layer, the third microfluidic channel on the eighth layer, and the biochip at the bottom of the eighth layer. In other words, the microfluidic channels through which blood flows and the microfluidic channels through which the test fluid flows are more clearly arranged in layers, so that the blood and test fluid flowing into the biochip separately will not interfere with each other. Another design features a three-layer biochip unit consisting of a fifth, seventh, and eighth layer, arranged in sequence. The fourth opening is located on the fifth layer, the third opening and the second microchannel are located on the seventh layer, and the third microchannel is located on the eighth layer, passing through a third recess in the eighth layer before reaching the biochip. The biochip is located at the bottom of the eighth layer. In other words, in addition to arranging the microchannels for blood and the test fluid in layers, the recess also provides a reservoir-like buffer between the test fluid entering the biochip and reaching the biochip, ensuring a stable and continuous flow of the test fluid.
[0016] In addition, to assist the flow of liquid through the microchannels and reduce the flow obstruction caused by bends in the microchannels (whether horizontal or vertical) or even due to reagents in the microchannels or the cross-sectional dimensions of the microchannels, a gas pump can be used to continuously input gas into one or more microchannels to assist in pushing the liquid. For example, a blood reagent unit can include a first gas opening and a first gas microchannel. Gas entering from the first gas opening will flow through the first gas microchannel and into the first microchannel, thereby promoting the flow of blood. For example, a biochip unit can include a second gas opening and a second gas microchannel. Gas entering from the second gas opening will flow through the second gas microchannel and into the third microchannel, thereby promoting the flow of the test liquid. Here, the first gas opening and the second gas opening can be connected to a gas pump, a gas cylinder, or other gas source to receive gas with a pressure sufficient to push the liquid through the microchannels.
[0017] Furthermore, since the test fluid and blood flow separately into the biochip, if not properly cleared, they could accumulate on the biochip and affect subsequent biochip operation. Therefore, a waste liquid reservoir and a waste liquid drainage port can be arranged at the bottom of the biochip unit. The waste liquid reservoir is connected to the biochip to temporarily store the blood and test fluid flowing through the biochip, and the waste liquid drainage port is connected to the waste liquid reservoir to drain the blood and test fluid from the waste liquid reservoir and out of the microfluidic biochip detection device.
[0018] According to the basic concept of the present invention, the present invention proposes a method for detecting blood using a microfluidic biochip detection device, which has the following basic steps. First, the special components of the blood are detected as needed, and the special reagents, special detection liquids and special biochips that need to be used are determined. Secondly, a microfluidic biochip detection device with special reagents and special biochips is provided. Next, the special detection liquid is input into the microfluidic biochip detection device to obtain first reaction data between the special detection liquid and the special biochip. Then, blood is input into the microfluidic biochip detection device so that the special biochip and the blood treated with the special reagent interact to change the state of the special biochip. Next, the special detection liquid is input into the microfluidic biochip detection device again to obtain second reaction data between the special detection liquid and the special biochip with the changed state. Finally, the first reaction data and the second reaction data are compared to determine the status of the special components of the blood.
[0019] Obviously, compared to the microfluidic biochip detection device using conventional technology that integrates multiple microchannels / reagents on the same flat plate, a major feature of the present invention is that the corresponding reagents and biochips can be selected according to the components in the blood that need to be detected, and then assembled into the required microfluidic biochip detection device. Then, just like the previous technology, the detection fluid, blood, and detection fluid are allowed to flow through the biochip in sequence, and the blood condition is determined by comparing the data obtained from the reaction between the biochip and blood before and after the biochip condition is changed by the blood.
[0020] Therefore, after testing a previous batch of blood and before testing a next batch of blood, if the first specific component to be tested for the previous batch of blood is different from the second specific component to be tested for the second batch of blood, or even if the two batches of blood are to be tested for the same specific component in different ways, the corresponding blood reagent unit and biochip unit can be selected based on the second specific component of the second batch of blood, or even based on the different tests to be performed on the same specific component, and a microfluidic biochip testing device different from the previously used one can be assembled. Next, the specific test liquid is input into the biochip unit, blood is input into the blood reagent unit, and the specific test liquid is input into the biochip unit in sequence. The first reaction data and the second reaction data obtained are then compared to determine the status of the second specific component or the different test results for the same specific component.
[0021] Since the method proposed in the present invention utilizes the microfluidic biochip detection device proposed in the present invention, the various changes of the related microfluidic biochip detection device have been described above and do not need to be described again here.
[0022] The advantages of the present invention over the prior art are significant. Because the blood reagent unit and the biochip unit can be combined or separated, blood reagent units and biochip units containing the required reagents and biochips can be selected based on the blood component or blood test being tested, and assembled into a microfluidic biochip detection device. This allows for flexible use, allowing for a high degree of flexibility. Medical personnel only need to prepare a variety of blood reagent units and biochip units, allowing them to assemble a microfluidic biochip detection device as needed. Furthermore, conventional techniques require pre-assembly of multiple potential reagents, microfluidics, and biochips into a single microfluidic biochip detection device. This inevitably leads to the risk of the entire microfluidic biochip detection device failing to function properly due to the depletion of reagents reacting with the flowing blood, the clogging of a microfluidic channel by impurities in the blood, or even a malfunction of the biochip. This results in low efficiency and high costs, necessitating repair or even complete disposal. In contrast, the present invention allows for the simple removal of problematic units and replacement with new ones, reducing not only the cost of wear and tear but also simplifying maintenance costs. For example, if a specific reagent in a blood reagent unit is depleted, the unit can be removed and replaced with another blood reagent unit containing a sufficient amount of the same reagent to form the desired microfluidic biochip detection device, leaving the biochip unit completely unaffected. Furthermore, because blood and test fluid flow to the biochip via separate microchannels, the possibility of vertically arranging multiple microchannels allows for a virtually unlimited number of microchannels to be connected to the same biochip, as long as the blood and test fluid can flow properly from the microchannels to the biochip (e.g., by dripping properly from the microchannel openings). Thus, a blood reagent unit can be expanded to include multiple microchannels corresponding to different reagents or different bloods to be tested, and a biochip unit can also be expanded to include multiple microchannels corresponding to multiple bloods from a blood reagent unit or even multiple different test fluids. It should be emphasized that, in conventional technology, since all microfluidic channels and biochips are on the same plate (the same plane), the area and outline of the biochip limit the upper limit of the number of microfluidic channels that can be connected. Incidentally, although conventional technology has the advantages of simple manufacturing and less prone to leakage of blood or test fluid by placing everything on the same plate, since connecting hardware components like building blocks and preventing liquid leakage by applying pressure, using laser fusion, or using O-rings are already common commercial technologies, the present invention does not have any technical difficulties in practical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The above and other features, advantages and aspects of the embodiments of the present invention will become more apparent with reference to the following detailed description in conjunction with the accompanying drawings. In the accompanying drawings, the same or similar reference numerals represent the same or similar elements.
[0024] FIG. 1A to FIG. 1D illustrate a microfluidic biochip detection device according to the present invention.
[0025] FIG. 2A to FIG. 2E illustrate a specific design of the microfluidic biochip detection device proposed in the present invention.
[0026] 3A to 3D illustrate a method for detecting a microfluidic biochip according to the present invention. DETAILED DESCRIPTION
[0027] The following describes the present invention and some preferred embodiments thereof to facilitate understanding of the features of the present invention by those skilled in the art. While preferred embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention may be implemented in various forms and is not intended to be limited by the embodiments set forth herein. Rather, these embodiments are provided to make the present invention more thorough and complete and to fully convey the scope of the present invention to those skilled in the art.
[0028] As used herein, the term "including" and its variations represent open inclusion, i.e., "including but not limited to." Unless otherwise stated, the term "or" means "and / or." The term "based on" means "based at least in part on." The terms "one example embodiment" and "an embodiment" mean "at least one example embodiment." The term "another embodiment" means "at least one additional embodiment." The terms "first," "second," etc. may refer to different or identical objects.
[0029] FIG1A illustrates the basic architecture of the microfluidic biochip detection device proposed in the present invention. As shown in FIG1A , the microfluidic biochip detection device 100 comprises two components: a blood reagent unit 101, which contains a first microfluidic channel 1011 through which blood can flow and a reagent 1012 located within the first microfluidic channel 1011. The biochip unit 102 comprises a second microfluidic channel 1021 through which blood can flow, a third microfluidic channel 1022 through which a test solution can flow, and a biochip 1023. When the blood reagent unit 101 and the biochip unit 102 are connected, the first microfluidic channel 1011 connects to the second microfluidic channel 1021, allowing blood to flow from the blood reagent unit 101 into the biochip unit 102. Furthermore, both the second microfluidic channel 1022 and the third microfluidic channel 1023 have openings adjacent to the biochip 1023, allowing blood and the test solution to flow appropriately through the corresponding openings to the biochip 1023 and react therewith. Thereby, the blood can first react with the reagent 1012 in the blood reagent unit 101 before contacting the biochip 1023 and reacting therewith. In addition, the blood and the test solution can be separately transferred to the biochip 1023 and reacted therewith.
[0030] Furthermore, to facilitate the flow of blood and test fluid to biochip 1023 and to facilitate the application of blood and test fluid to microfluidic biochip testing device 100, a common structure of the microfluidic biochip testing device proposed by the present invention, as shown in FIG1B , is configured such that first opening 1013 through which blood enters blood reagent unit 101 and second opening 1024 through which test fluid enters biochip unit 102 are both located on the same side of the microfluidic biochip testing device, and biochip 1023 is located on opposite sides of the microfluidic biochip testing device 100. By locating first opening 1013 and second opening 1024 at the top, an operator of microfluidic biochip testing device 100 can easily apply blood and test fluid, and blood and test fluid flow generally from top to bottom into biochip 1023, facilitating the configuration of first microfluidic channel 1011, second microfluidic channel 1021, and third microfluidic channel 1022. Of course, purely in terms of the basic structure of the present invention, the first opening 1013 and the second opening 1024 can be located on different surfaces of the microfluidic biochip testing device 100, as long as the user can apply blood and the test fluid. Furthermore, the first opening 1013 and / or the second opening 1024 do not necessarily need to be located on opposite sides of the microfluidic biochip testing device 100 from the biochip 1023, as long as blood and the test fluid can flow and reach the biochip 1023.
[0031] Obviously, the present invention only requires that blood flow from the blood reagent unit 101 into the biochip unit 102 be free of spillage or leakage, and does not require numerous restrictions on the outline, size, shape, or internal configuration of the blood reagent unit 101 and the biochip unit 102. For example, FIG1A illustrates a scenario where the blood reagent unit 101 and the biochip unit 102 have identical dimensions and outlines, but differ in the distribution of the microfluidic channels within them (ignoring that the biochip 1023 resides only in the biochip unit 102). For example, FIG1B illustrates a scenario where the blood reagent unit 101 is smaller and the biochip unit 102 is larger. After all, the biochip 102 requires separate placement of the second microfluidic channel 1021, the third microfluidic channel 1022, and the biochip 1024. Compared to the blood reagent unit 101, which only requires the first microfluidic channel 1021, a larger biochip unit 102 provides more space for maneuvering. Of course, although not specifically illustrated, the contours, dimensions, and internal structures of the two units are subject to various variations, as long as the adjacent surfaces of the two units remain unchanged or, in other words, as long as the microfluidic channels required for blood flow between the two units are securely connected. For example, the interiors of the blood reagent unit 101 and the biochip unit 102 can each have a multi-layered structure, with the first opening 1013 for blood entry, the second opening 1024 for test fluid entry, and the three microfluidic channels 1011 / 1021 / 1022 and the biochip 1023 being located on the same layer or on different layers. In other words, the internal configurations of each unit can be adjusted as needed. For example, the first opening 1013 and the second opening 1024 for blood and test fluid entry could be located on the same layer, while the microfluidic channels 1011 / 1021 / 1022 could be located on different layers. For another example, each microchannel 1011 / 1021 / 1022 can be located on the same layer or on a different layer as the biochip 1023, or even when a microchannel is long enough (such as a first microchannel 1011 that needs to be arranged to place multiple reagents 1012), different parts of the microchannel can be located on different layers. For example, there can be multiple first microchannels 1011 inside the blood reagent unit 101, each having the same or different reagents 1012, so that the same test can be performed on different blood samples or different tests (detecting different blood components) can be performed on the same or different blood samples in the same blood reagent unit 101. Of course, the number of second microchannels 1021 inside the biochip unit 102 also needs to be increased accordingly. For example, the same first microchannel 1011 can have more than one reagent 1012, that is, more than one test can be performed on the same blood sample in sequence.1A and 1B , as long as blood and test fluid can flow from the second microchannel 1022 and the third microchannel 1023 to the biochip 1023 respectively, for any microchannel, the opening for allowing blood or test fluid to leave and go to the biochip 1023 can be at its end or far away from its end.
[0032] In addition, to ensure the flow of blood and / or test fluid, as shown in Figures 1C and 1D, the blood reagent unit 101 further includes a first gas opening 1014 and a first gas microchannel 1015. Gas entering through the first gas opening 1014 flows through the first gas microchannel 1015 and into the first microchannel 1011, thereby promoting the flow of blood. Conversely, the biochip unit 102 further includes a second gas opening 1025 and a second gas microchannel 1026. Gas entering through the second gas opening 1025 flows through the second gas microchannel 1026 and into the third microchannel 1022, thereby promoting the flow of the test fluid. Of course, although not specifically shown, the biochip unit 102 may also include another set of gas openings and gas microchannels for receiving gas to promote the flow of blood in the second microchannel 1021. Generally speaking, the first gas opening 1014 and the second gas opening 1025 can be connected to a gas pump, a gas cylinder or other gas source to continuously receive gas, especially nitrogen or inert gas with low reactivity that will hardly affect the properties of blood and test fluid.
[0033] Furthermore, to manage the blood and test fluid flowing into biochip 1023, and in particular to prevent interference between the blood and test fluid flowing into biochip 1023 and affecting the normal operation of biochip 1023, the bottom of biochip unit 102 further includes a waste liquid reservoir and a waste liquid drain port, although details are not specifically shown. The waste liquid reservoir is connected to biochip 1023 to temporarily store the blood and test fluid flowing through biochip 1023, while the waste liquid drain port is connected to the waste liquid reservoir to drain the blood and test fluid from the waste liquid reservoir (away from biochip unit 102). Additionally, although not specifically shown, an O-ring can be placed near the opening of the first microfluidic channel 1011 in the housing of the blood reagent unit 101, or near the opening of the second microfluidic channel 1021 in the housing of the biochip, to prevent accidental blood leakage when the two units are connected, or laser fusion can be used, or mechanical pressure can be applied.
[0034] As an example of the microfluidic biochip detection device proposed by the present invention, Figures 2A to 2E show a specific design. Here, microfluidic biochip detection device 200 includes a blood reagent unit 201 and a biochip unit 202. The blood reagent unit 201 has a smaller area and depth, while the biochip unit 202 has a larger area and depth. As shown in Figures 2A and 2B, from the top and a side view, the blood reagent unit 201 and the biochip unit 202 are located in different parts of the microfluidic biochip detection device 200. However, from the bottom and a side view, the blood reagent unit 201 is located above the biochip unit 202. In other words, the overall outline of the biochip unit 202 resembles a staircase structure, with the blood reagent unit 201 located on this staircase. This leaves more space in the biochip unit 202 for the microfluidic channels for blood flow, the microfluidic channels for the test fluid, and the biochip.
[0035] As shown in Figure 2C, the blood reagent unit 201 is a three-layer structure. The top layer consists of only a first opening 2011 and a second opening 2012 for blood and gas, respectively. The middle layer comprises a first recess 2013 and a second recess 2014, each separated from the other. The bottom layer comprises a blood microchannel 2015, with its ends located below the bottom openings of the first recess 2012 and the second recess 2014, respectively. The first recess 2013 is connected to both openings 2011 / 2012, thereby receiving blood and gas from the outside. Blood entering the first recess 2013 first passes through its bottom opening into the blood microchannel 2015 and then enters the second recess 2014 through the bottom opening of the second recess 2014. One or more reagents within the blood microchannel 2015, or even within the first recess 2013 and / or the second recess 2014, can interact with one or more components of the blood as it flows through. The reagent-treated blood exiting the second groove 2014 flows out of the blood reagent unit 201 through the third opening 2016 and into the biochip unit 202. An O-ring 2027 (only the O-ring embodiment is shown here, and other possible embodiments are not shown) is located on the outer shell of the blood reagent unit 201 adjacent to the third opening 2016 to prevent abnormal leakage of blood between the blood reagent unit 201 and the biochip unit 202. Here, the first groove 2013 and the second groove 2014 can be used to regulate and stabilize blood flow, provide a buffer space for blood and reagents to interact effectively, or even provide space for one or more reagents. In certain related but not specifically illustrated variations, the first groove 2013 and / or the second groove 2014 can have a larger area and a deeper depth, or can have a cross-sectional profile and dimensions comparable to those of the blood microchannel 2025, depending on whether blood can flow smoothly from the first opening 2011 to the third opening 2016. Similarly, although the blood microchannel 2015 shown in the current diagram is merely a straight groove with its two ends located below the first groove 2013 and the second groove 2014, respectively, in certain related but not specifically illustrated variations, the blood microchannel 2015 may be arranged in a meandering pattern at the bottom layer, as long as it can receive blood from the first groove 2013 and allow blood to enter the second groove 2014. Furthermore, if the blood microchannel 2015 is to hold reagents for reacting with blood, in certain related but not specifically illustrated variations, a portion of the blood microchannel 2015 may be located in the middle layer, that is, the openings of the first groove 2013 and / or the second groove 2014 are not located at their bottoms but at their sides.
[0036] As shown in Figure 2D, the biochip unit 202 also has a three-layer structure. The top layer consists of only the fourth opening 2021 and the fifth opening 2022, for admitting test fluid and gas, respectively. The middle layer contains a blood microchannel 2023, while the bottom layer contains a test fluid microchannel 2024 and a third recess 2025. A biochip 2026 is also located at the bottom of the bottom layer. The blood microchannel 2023 connects to the third opening 2016 of the blood reagent unit 201 and has an opening near the biochip 2026, allowing the reagent-treated blood from the blood reagent unit 201 to flow to the biochip 2026. The third recess 2023 connects to these two openings 2021 / 2022 to receive test fluid and gas from the outside. Obviously, the third recess 2023 can be used to regulate and stabilize the flow of the test fluid. In certain related variations (not specifically shown), the third recess 2023 may have a larger area and a greater depth, but may also have a similar cross-sectional profile and dimensions to the test liquid microchannel 2024, depending on whether the test liquid can flow smoothly from the fourth opening 2021 to the top of the biochip 2026. Similarly, the test liquid microchannel 2024 also has an opening near the biochip 2026, through which the test liquid can flow to the biochip 2026. Here, since both the blood microchannel 2023 and the test liquid microchannel 2024 only need to allow blood and test liquid to flow smoothly to the top of the biochip 2026, their layout (or outline) can be simple lines, as long as they are separated from each other to ensure that the blood and test liquid can contact the biochip 2026 separately. Furthermore, at the bottom of the lowest layer, biochip 2026 can receive the blood and test fluid flowing thereto, and near the lowest layer of biochip 2026, there can be an area for placing a waste liquid tank and a waste liquid drainage hole, such as the processing area 2027 shown in Figure 2E. Here, since many conventional technologies can be used for storing and draining liquids (blood and test fluid), such as a combination of a large groove, some microchannels, and one or more openings, the relevant details do not need to be specifically illustrated.
[0037] FIG3A illustrates a method for testing blood using a microfluidic biochip detection device according to the present invention, which includes the following basic steps. First, as shown in step 301, the specific blood component is detected, and the required specific reagent, specific detection fluid, and specific biochip are determined. Second, as shown in step 302, a microfluidic biochip detection device containing the specific reagent and the specific biochip is provided. Third, as shown in step 303, the specific detection fluid is input into the microfluidic biochip detection device to obtain first reaction data between the specific detection fluid and the specific biochip. Then, as shown in step 304, blood is input into the microfluidic biochip detection device, allowing the specific biochip to interact with the blood treated with the specific reagent, thereby changing the state of the specific biochip. Next, as shown in step 305, the specific detection fluid is again input into the microfluidic biochip detection device to obtain second reaction data between the specific detection fluid and the changed state of the specific biochip. Finally, as shown in step 306, the first reaction data is compared with the second reaction data to determine the status of the specific blood component. Here, the microfluidic biochip detection device used is composed of the blood reagent unit and the biochip unit described in the above paragraph connected to each other in a detachable manner, so the relevant hardware details and changes can be omitted and not repeated.
[0038] Clearly, compared to the common design of existing commercial microfluidic biochip detection devices, the main feature of the method proposed in the present invention lies in steps 301 and 302, which flexibly select blood reagent units with corresponding reagents and biochip units with corresponding biochips to assemble the microfluidic biochip detection device to be used, based on the blood sample to be tested and how the blood sample is to be tested. That is, before testing a batch of blood, the corresponding blood reagent units and biochip units can be selected based on the specific components of the blood to be tested. That is, after testing a previous batch of blood and before testing a next batch of blood, if the first specific component to be tested in the previous batch of blood is different from the second specific component to be tested in the second batch of blood, the corresponding blood reagent units and biochip units can be selected based on the second specific component of the second batch of blood. Figures 3B to 3D summarize the process flow of this method. First, a plurality of different blood reagent units 331 to 339 with different reagents (3301 to 3309) and a plurality of different biochip units 341 to 349 with different biochips (3401 to 3409) are provided. Next, to detect a first component in a first blood sample, a blood reagent unit 332 with reagent 3302 and a biochip unit 342 with biochip 3402 are selected and assembled to form a microfluidic biochip detection device 3501. Next, to detect a second component in a second blood sample, a blood reagent unit 337 with reagent 3307 and a biochip unit 347 with biochip 3407 are selected and assembled to form a microfluidic biochip detection device 3502. Once the two selected units are assembled into the microfluidic biochip detection device, a specific test fluid can be sequentially input into the biochip unit, blood can be input into the blood reagent unit, and the specific test fluid can be input into the biochip unit. The first and second reaction data obtained can then be compared to determine the status of the second specific component. Since the method for obtaining blood test results from the sequential reactions between the biochip and the test fluid / blood can be implemented using commercial biochips, the detailed description will not be repeated here.
[0039] In summary, the present invention is subject to numerous modifications and variations based on the description of the embodiments above. Therefore, it should be understood within the scope of the appended claims. In addition to the detailed description above, the present invention may be widely implemented in other embodiments. The above descriptions are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Any equivalent changes or modifications that do not depart from the spirit of the present invention are intended to be included within the scope of the following claims.
Claims
1. A microfluidic biochip detection device, comprising: A blood reagent unit, which has at least a first microfluidic channel, through which the blood to be tested flows; as well as A biochip unit, which at least has a second microchannel, a third microchannel and a biochip, wherein the blood from the first microchannel of the blood reagent unit flows through the second microchannel to reach the biochip, and the detection liquid flows through the third microchannel to reach the biochip; Wherein, at least one reagent is located in the first microchannel to react with a component of the blood flowing through; The second microchannel and the third microchannel are separated from each other, so that the blood and the detection liquid flow to the biochip separately.
2. The microfluidic biochip detection device according to claim 1, wherein: A blood reagent unit further comprising a first opening and a second opening, wherein the blood entering from the first opening first flows through the first microchannel and then flows out from the second opening; as well as The biochip unit further has a third opening and a fourth opening. The blood from the blood reagent unit enters the second microchannel from the third opening, and the detection liquid enters the third microchannel from the fourth opening.
3. The microfluidic biochip detection device according to claim 2, wherein: The blood reagent unit and the biochip unit are detachably connected to each other.
4. The microfluidic biochip detection device according to claim 3, wherein: When the blood reagent unit and the biochip unit are connected to each other, the second opening of the blood reagent unit is connected to the third opening of the biochip unit, so that blood will not leak outside the blood reagent unit and the biochip unit during the process of flowing from the blood reagent unit to the biochip unit.
5. The microfluidic biochip detection device according to claim 2, wherein: The second opening is adjacent to the third opening, the first opening and the fourth opening are located on the same side of the microfluidic biochip detection device, and the first opening and the fourth opening are located on opposite sides of the microfluidic biochip detection device with the biochip.
6. The microfluidic biochip detection device according to claim 2, further comprising at least one of the following: A portion of the first microfluidic channel has a reagent for reacting with a component of blood; Different parts of the first microfluidic channel have different reagents for reacting differently with certain components of the blood; and Different parts of the first microfluidic channel have different reagents for reacting differently with different components of the blood.
7. The microfluidic biochip detection device according to claim 6, further comprising at least one of the following: At least one reagent is coated on the first microfluidic channel; and The types of reagents include: Separating agent, erythrocyte precipitant, leukocyte precipitant, activated carbon and silver nitrate.
8. The microfluidic biochip detection device according to claim 2, further comprising at least one of the following: A first filter, located at the first opening, for filtering impurities in the blood; and The second filter is located between the second opening and the third opening and is used to filter impurities in the blood.
9. The microfluidic biochip detection device according to claim 6, wherein: The blood reagent unit is a double-layer structure consisting of a first layer and a second layer arranged in sequence, wherein the first opening is located in the first layer, and the second opening and the first microchannel are located in the second layer.
10. The microfluidic biochip detection device according to claim 6, wherein: The blood reagent unit is a three-layer structure consisting of a first layer, a third layer and a fourth layer arranged in sequence, wherein the first opening is located in the first layer, the second opening is located in the third layer, and the first microchannel is located in the third layer and the fourth layer.
11. The microfluidic biochip detection device according to claim 6, wherein: The blood reagent unit is a three-layer structure consisting of a first layer, a third layer and a fourth layer arranged in sequence, wherein the first opening is located on the first layer, the second opening is located on the third layer, and the first microchannel is located on the fourth layer. The third layer further includes a first groove and a second groove, and the first microfluidic channel is connected to the first groove and the second groove respectively, so that at least one reagent is located in a portion of the first microfluidic channel between the first groove and the second groove.
12. The microfluidic biochip detection device according to claim 2, wherein: The biochip unit is a double-layer structure consisting of a fifth layer and a sixth layer arranged in sequence, wherein the fourth opening is located on the fifth layer, the third opening is located on the sixth layer, the second microchannel and the third microchannel are both located on the sixth layer, and the biochip is located at the bottom of the sixth layer.
13. The microfluidic biochip detection device according to claim 2, wherein: The biochip unit is a three-layer structure consisting of a fifth layer, a seventh layer and an eighth layer arranged in sequence, wherein the fourth opening is located on the fifth layer, the third opening is located on the seventh layer, the second microchannel is located on the seventh layer, the third microchannel is located on the eighth layer, and the biochip is located at the bottom of the eighth layer.
14. The microfluidic biochip detection device according to claim 2, wherein: The biochip unit is a three-layer structure consisting of a fifth layer, a seventh layer and an eighth layer arranged in sequence, wherein the fourth opening is located on the fifth layer, the third opening is located on the seventh layer, the second microchannel is located on the seventh layer, the third microchannel is located on the eighth layer and passes through the third groove on the eighth layer before reaching the top of the biochip, and the biochip is located at the bottom of the eighth layer.
15. The microfluidic biochip detection device according to claim 2, wherein: The blood reagent unit further includes a first gas opening and a first gas microchannel. The gas entering from the first gas opening flows through the first gas microchannel and enters the first microchannel, thereby promoting the flow of blood.
16. The microfluidic biochip detection device according to claim 2, wherein: The biochip unit further includes a second gas opening and a second gas microchannel. The gas entering from the second gas opening flows through the second gas microchannel and enters the third microchannel, thereby promoting the flow of the detection liquid.
17. The microfluidic biochip detection device according to claim 2, wherein: The bottom of the biochip unit also includes a waste liquid tank and a waste liquid discharge hole. The waste liquid tank is connected to the biochip to temporarily store the blood and detection liquid flowing through the biochip, and the waste liquid discharge hole is connected to the waste liquid tank to discharge the blood and detection liquid from the waste liquid tank.
18. A method for detecting blood using a microfluidic biochip detection device, comprising: Determine the special reagents, special test fluids and special biochips to be used based on the special components of the blood to be tested; Providing microfluidic biochip detection devices with special reagents and special biochips; Inputting a special detection liquid into the microfluidic biochip detection device to obtain first reaction data between the special detection liquid and the special biochip; Blood is input into the microfluidic biochip detection device, so that the special biochip The chip interacts with blood treated with a special reagent to change the state of the special biochip; Inputting the special detection liquid into the microfluidic biochip detection device again to obtain second reaction data between the special detection liquid and the special biochip with a changed state; and Comparing the first reaction data with the second reaction data to determine the status of the special component of the blood; Among them, the microfluidic biochip detection device includes a blood reagent unit and a biochip unit, the blood reagent unit has a first microfluidic channel and a special reagent located in the first microfluidic channel, and the biochip unit has a biochip and a second microfluidic channel and a third microfluidic channel separated from each other. The blood input into the blood reagent unit flows through the first microfluidic channel and the second microfluidic channel successively and arrives at the biochip after being treated with the special reagent, and the detection liquid input into the biochip unit flows through the third microfluidic channel and arrives at the biochip.
19. The method according to claim 18, wherein: The blood reagent unit and the biochip unit are connected to each other in a detachable manner.
20. The method according to claim 18, wherein: After testing the previous batch of blood and before testing the next batch of blood, if the first special component to be detected in the previous batch of blood is different from the second special component to be detected in the second batch of blood, first select the corresponding blood reagent unit and biochip unit according to the second special component of the second batch of blood and assemble them into the microfluidic biochip detection device, then input the special detection liquid into the biochip unit, input blood into the blood reagent unit, and input the special detection liquid into the biochip unit in sequence, and then compare the first reaction data and the second reaction data obtained to determine the status of the second special component.
21. The method according to claim 18, wherein: The blood reagent unit has a first opening, a second opening and a first microfluidic channel. The blood entering from the first opening will first flow through the first microfluidic channel and then flow out from the second opening. The biochip unit has a third opening, a fourth opening, a second microfluidic channel, a third microfluidic channel and a biochip. The blood from the blood reagent unit entering from the third opening will flow through the second microfluidic channel to reach the biochip, and the test liquid entering from the fourth opening will flow through the third microfluidic channel to reach the biochip. Here, the second microfluidic channel and the third microfluidic channel are separated from each other, so that the blood and the test liquid flow to the biochip separately.
22. The method of claim 18, further comprising at least one of the following: At least one reagent is coated on the first microfluidic channel; and The types of reagents include: Separating agent, erythrocyte precipitant, leukocyte precipitant, activated carbon and silver nitrate.
Citation Information
Patent Citations
ATP fluorescent micro-fluidic chip, bioluminescence continuous detection system and detection method
CN111889150A
Integrated point-of-care blood detection system and method
CN114728216A
Blood or tissue fluid collecting and processing chip and detection device and method
CN115227240A
Micro-channel biochip detection device and use method
CN117696134A
Double-layer micro-fluidic chip
CN212560268U
